Teresa Hemmerle

Otelfingen, ZH 8112, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma.

Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma.

Journal: Science translational medicine
Published: May 24, 2023

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.

Journal: Blood advances
Published: December 23, 2021

Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.

Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.

Journal: British journal of haematology
Published: January 24, 2021

Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.

Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.

Journal: European journal of cancer (Oxford, England : 1990)
Published: January 01, 2021

Immunocytokines are a promising immunotherapeutic approach against glioblastoma.

Immunocytokines are a promising immunotherapeutic approach against glioblastoma.

Journal: Science translational medicine
Published: February 09, 2020

Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation.

Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation.

Journal: JCI insight
Published: September 11, 2018

Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis.

Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis.

Journal: Rheumatology (Oxford, England)
Published: June 07, 2017

Targeted IL-4 therapy synergizes with dexamethasone to induce a state of tolerance by promoting Treg cells and macrophages in mice with arthritis.

Targeted IL-4 therapy synergizes with dexamethasone to induce a state of tolerance by promoting Treg cells and macrophages in mice with arthritis.

Journal: European journal of immunology
Published: November 28, 2015

The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model.

The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model.

Journal: Reproductive sciences (Thousand Oaks, Calif.)
Published: April 09, 2015

Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.

Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 13, 2014

Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis.

Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 06, 2014

The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.

The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.

Journal: Cancer immunology research
Published: May 06, 2014
Showing 1-12 of 20

Last Updated: 09/26/2026